Synonyms: AA-673 | Amlexanox® | Aphthasol® | CHX-3673
amlexanox is an approved drug (FDA (1996))
Compound class:
Synthetic organic
Comment: Amlexanox has anti-inflammatory [1], antiallergic and immunomodulatory actions [2]. Proposed to inhibit IKKδ and TBK1, albeit with low potency [5].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Used to treat asthma and allergic rhinitis in Japan and was approved in the US to treat aphthous ulcers [1]. Use of this drug is not currently approved in the US (old formulations have been discontinued) or EU. Other national approval agencies may continue to grant marketing authorisation. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Amlexanox's mechanism of action is not well-determined, but likely includes inhibition of histamine and leukotriene release [1], and possibly inhibition of phosphodiesterase [3-4]. Since PDE4 is prevalent in immune cells [6], this may be a target of amlexanox (see the CHEMBL link). |
External links ![]() |
For extended ADME data see the following: Drugs.com |